Literature DB >> 11994234

Population-based trends in pediatric hemolytic uremic syndrome in California, 1994-1999: substantial underreporting and public health implications.

Kate C Cummings1, Janet C Mohle-Boetani, S Benson Werner, Duc J Vugia.   

Abstract

This paper describes the epidemiology of childhood hemolytic uremic syndrome (HUS) in California, for which hospitalization data were used, and the proportion of cases reported to public health authorities. HUS discharge data for children < or =17 years of age were extracted from the population-based California Patient Discharge Data Set for 1994-1999 and were linked electronically with HUS reports to public health authorities. Incidence rates per 100,000 children were calculated. The authors identified 585 HUS hospitalizations; 369 were incident cases. The average HUS incidence rate was 0.67 (95% confidence interval: 0.61, 0.74); rates rose modestly from 1994 (0.59, 95% confidence interval: 0.44, 0.78) to 1997 (0.80, 95% confidence interval: 0.63, 10.0) and decreased modestly thereafter (0.59, 95% confidence interval: 0.45, 0.77). Rates were highest for northern California children < or =5 years of age (1.85, 95% confidence interval: 1.55, 2.19). The hospital case-fatality rate was 2.7% (95% confidence interval: 1.1, 4.4); the median charge was $39,500 per child. Only 43.9% of HUS cases in the California Patient Discharge Data Set were reported to public health authorities. Despite heightened efforts to control Shiga toxin-producing Escherichia coli exposures (the predominant cause of childhood HUS in the United States), HUS incidence rates remained relatively stable in California. Reporting HUS cases to public health authorities is important for disease control.

Entities:  

Mesh:

Year:  2002        PMID: 11994234     DOI: 10.1093/aje/155.10.941

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  12 in total

1.  Diarrhea-associated hemolytic uremic syndrome in southern Alberta: A long-term single-centre experience.

Authors:  Silviu Grisaru; Julian P Midgley; Lorraine A Hamiwka; Andrew W Wade; Susan M Samuel
Journal:  Paediatr Child Health       Date:  2011-06       Impact factor: 2.253

2.  Haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran.

Authors:  Francesco Rodeghiero
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

3.  Clinical and laboratory patterns of the haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran.

Authors:  Mehran Karimi; Ameneh Sabzi; Flora Peyvandi; Pier Mannuccio Mannucci
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

4.  Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome.

Authors:  Marie-Agnès Dragon-Durey; Sidharth Kumar Sethi; Arvind Bagga; Caroline Blanc; Jacques Blouin; Bruno Ranchin; Jean-Luc André; Nobuaki Takagi; Hae Il Cheong; Pankaj Hari; Moglie Le Quintrec; Patrick Niaudet; Chantal Loirat; Wolf Herman Fridman; Véronique Frémeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2010-11-04       Impact factor: 10.121

5.  Characteristics of children with sporadic hemolytic uremic syndrome in a single Northern California center.

Authors:  Gia Oh; Keith K Lau
Journal:  Int Urol Nephrol       Date:  2011-11-25       Impact factor: 2.370

6.  Serum Transaminases at Presentation and Association with Acute Dialysis in Children with Hemolytic Uremic Syndrome.

Authors:  Saurabh Talathi; Margaux Barnes; Inmaculada Aban; Reed Dimmitt; David J Askenazi
Journal:  Kidney360       Date:  2020-03-19

7.  Evaluation of the surveillance of hemolytic uremic syndrome in British Columbia: should it remain reportable?

Authors:  Kathleen Laberge; Eleni Galanis
Journal:  Can J Public Health       Date:  2008 Jul-Aug

8.  Hemolytic uremic syndrome incidence in New York.

Authors:  Hwa-Gan H Chang; Boldtsetseg Tserenpuntsag; Marilyn Kacica; Perry F Smith; Dale L Morse
Journal:  Emerg Infect Dis       Date:  2004-05       Impact factor: 6.883

9.  Sex steroids do not affect shigatoxin cytotoxicity on human renal tubular or glomerular cells.

Authors:  Alisa K Hughes; Douglas I Schmid; Donald E Kohan
Journal:  BMC Nephrol       Date:  2002-08-14       Impact factor: 2.388

Review 10.  Management of hemolytic-uremic syndrome in children.

Authors:  Silviu Grisaru
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.